Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Antioxidant properties of the triaminopyridine, flupirtine.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Chemotherapeutics in the treatment of multiple sclerosis.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Repurposing drugs for disease modification in multiple sclerosis
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.

Pages